| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Aberrant GSK3β nuclear localization promotes AML growth and drug resistance
|
Ignatz-Hoover, James J.
|
|
|
|
21 |
p. 2890-2903
|
artikel
|
| 2 |
Abortive γδTCR rearrangements suggest ILC2s are derived from T-cell precursors
|
Shin, Samuel B.
|
|
|
|
21 |
p. 5362-5372
|
artikel
|
| 3 |
Activated platelet-based inhibition of fibrinolysis via thrombin-activatable fibrinolysis inhibitor activation system
|
Suzuki, Yuko
|
|
|
|
21 |
p. 5501-5511
|
artikel
|
| 4 |
Activity of eltrombopag in severe aplastic anemia
|
Scheinberg, Phillip
|
|
|
|
21 |
p. 3054-3062
|
artikel
|
| 5 |
Adapting a patient-centered communication tool for older patients with acute myeloid leukemia and their oncologist
|
Watson, Erin
|
|
|
|
21 |
p. 5707-5710
|
artikel
|
| 6 |
A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression
|
Abrisqueta, Pau
|
|
|
|
21 |
p. 5763-5773
|
artikel
|
| 7 |
A genetic modifier of venous thrombosis in zebrafish reveals a functional role for fibrinogen AαE in early hemostasis
|
Freire, Cristina
|
|
|
|
21 |
p. 5480-5491
|
artikel
|
| 8 |
A geno-clinical decision model for the diagnosis of myelodysplastic syndromes
|
Radakovich, Nathan
|
|
|
|
21 |
p. 4361-4369
|
artikel
|
| 9 |
Age-specific impact of type I interferons on cerebral thrombosis and inflammation
|
Denorme, Frederik
|
|
|
|
21 |
p. 6672-6675
|
artikel
|
| 10 |
AML with complex karyotype: extreme genomic complexity revealed by combined long-read sequencing and Hi-C technology
|
Klever, Marius-Konstantin
|
|
|
|
21 |
p. 6520-6531
|
artikel
|
| 11 |
Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation
|
Yamamoto, Chihiro
|
|
|
|
21 |
p. 3266-3277
|
artikel
|
| 12 |
A novel class of ZNF384 aberrations in acute leukemia
|
Zaliova, Marketa
|
|
|
|
21 |
p. 4393-4397
|
artikel
|
| 13 |
A novel FAS mutation with variable expressivity in a family with unicentric and idiopathic multicentric Castleman disease
|
Baker, Turner S.
|
|
|
|
21 |
p. 2959-2963
|
artikel
|
| 14 |
Antibody-mediated immune suppression by antigen modulation is antigen-specific
|
Maier, Cheryl L.
|
|
|
|
21 |
p. 2986-3000
|
artikel
|
| 15 |
Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia
|
Gill, Saar
|
|
|
|
21 |
p. 5774-5785
|
artikel
|
| 16 |
Anti-cysteine/spacer antibodies that open ADAMTS13 are a common feature in iTTP
|
De Waele, Laure
|
|
|
|
21 |
p. 4480-4484
|
artikel
|
| 17 |
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients
|
Oran, Betül
|
|
|
|
21 |
p. 5580-5588
|
artikel
|
| 18 |
A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease
|
Whangbo, Jennifer S.
|
|
|
|
21 |
p. 5786-5796
|
artikel
|
| 19 |
A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma
|
Strati, Paolo
|
|
|
|
21 |
p. 6785-6789
|
artikel
|
| 20 |
A phase 2 trial of defibrotide for the prevention of chimeric antigen receptor T-cell–associated neurotoxicity syndrome
|
Jacobson, Caron A.
|
|
|
|
21 |
p. 6790-6799
|
artikel
|
| 21 |
Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS
|
Guo, Wancheng
|
|
|
|
21 |
p. 6676-6684
|
artikel
|
| 22 |
ASH Clinical Practice Guidelines: strategies to stay up-to-date
|
Cheung, Matthew C.
|
|
|
|
21 |
p. 6707-6709
|
artikel
|
| 23 |
Association between clinical outcomes and metformin use in adults with sickle cell disease and diabetes mellitus
|
Badawy, Sherif M.
|
|
|
|
21 |
p. 3297-3306
|
artikel
|
| 24 |
Associations between hematology/oncology fellows' training and mentorship experiences and hematology-only career plans
|
Masselink, Leah E.
|
|
|
|
21 |
p. 3278-3286
|
artikel
|
| 25 |
A unique microenvironment in the developing liver supports the expansion of megakaryocyte progenitors
|
Brouard, Nathalie
|
|
|
|
21 |
p. 1854-1866
|
artikel
|
| 26 |
Blast phenotype and comutations in acute myeloid leukemia with mutated NPM1 influence disease biology and outcome
|
Mason, Emily F.
|
|
|
|
21 |
p. 3322-3332
|
artikel
|
| 27 |
Blockade of TIM-1 on the donor graft ameliorates graft-versus-host disease following hematopoietic cell transplantation
|
Iliopoulou, Bettina P.
|
|
|
|
21 |
p. 3419-3431
|
artikel
|
| 28 |
B-lymphoblastic leukemia arising in a patient with chronic neutrophilic leukemia
|
Boddy, Craig S.
|
|
|
|
21 |
p. 5389-5392
|
artikel
|
| 29 |
Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia
|
Mangaonkar, Abhishek A.
|
|
|
|
21 |
p. 5425-5430
|
artikel
|
| 30 |
Bone marrow stroma cells promote induction of a chemoresistant and prognostic unfavorable S100A8/A9high AML cell subset
|
Böttcher, Martin
|
|
|
|
21 |
p. 5685-5697
|
artikel
|
| 31 |
Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort
|
Bowers, Jackson T.
|
|
|
|
21 |
p. 6630-6638
|
artikel
|
| 32 |
Buettner R, Morales C, Caserta E, et al. Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting. Blood Adv. 2019;3(7):1027-1032.
|
|
|
|
|
21 |
p. 5797
|
artikel
|
| 33 |
Calcitonin receptor‐like (CALCRL) is a marker of stemness and an independent predictor of outcome in pediatric AML
|
Angenendt, Linus
|
|
|
|
21 |
p. 4413-4421
|
artikel
|
| 34 |
CAR T-cell therapy: is it prime time in myeloma?
|
Sidana, Surbhi
|
|
|
|
21 |
p. 3473-3480
|
artikel
|
| 35 |
CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies
|
Perez de Acha, Olivia
|
|
|
|
21 |
p. 6430-6440
|
artikel
|
| 36 |
CD34 expression does not correlate with immunophenotypic stem cell or progenitor content in human cord blood products
|
Mantri, Sruthi
|
|
|
|
21 |
p. 5357-5361
|
artikel
|
| 37 |
CD200 expression marks leukemia stem cells in human AML
|
Ho, Jenny M.
|
|
|
|
21 |
p. 5402-5413
|
artikel
|
| 38 |
CD16+ monocytes give rise to CD103+RALDH2+TCF4+ dendritic cells with unique transcriptional and immunological features
|
Wacleche, Vanessa Sue
|
|
|
|
21 |
p. 2862-2878
|
artikel
|
| 39 |
CD4 T cells specific for factor VIII are present at high frequency in healthy donors and comprise naïve and memory cells
|
Meunier, Sylvain
|
|
|
|
21 |
p. 1842-1847
|
artikel
|
| 40 |
Cigarette smoke exposure accelerates AML progression in FLT3-ITD models
|
Figueroa, Mary
|
|
|
|
21 |
p. 6624-6629
|
artikel
|
| 41 |
Circulating microbial cell–free DNA is increased during neutropenia after hematopoietic stem cell transplantation
|
Blair, Lily M.
|
|
|
|
21 |
p. 6744-6750
|
artikel
|
| 42 |
Clinical impact of BAALC expression in high-risk acute promyelocytic leukemia
|
Lucena-Araujo, Antonio R.
|
|
|
|
21 |
p. 1807-1814
|
artikel
|
| 43 |
CLL-IPI applied in Binet A CLL: a nationwide cohort study
|
Rotbain, Emelie C.
|
|
|
|
21 |
p. 5698-5701
|
artikel
|
| 44 |
Clonal expansion of CD8+ T cells reflects graft-versus-leukemia activity and precedes durable remission following DLI
|
Schultze-Florey, Christian R.
|
|
|
|
21 |
p. 4485-4499
|
artikel
|
| 45 |
Commentary on the 2023 ASH guidelines for thrombophilia testing in venous thromboembolism
|
Juneja, Manu
|
|
|
|
21 |
p. 6428-6429
|
artikel
|
| 46 |
Contraception, pregnancy, and STI counseling and care among transitioning young adults with sickle cell disease
|
Shankar, Divya
|
|
|
|
21 |
p. 6668-6671
|
artikel
|
| 47 |
Cranberry A-type proanthocyanidins selectively target acute myeloid leukemia cells
|
Bystrom, Laura M.
|
|
|
|
21 |
p. 3261-3265
|
artikel
|
| 48 |
Crucial roles of red blood cells and platelets in whole blood thrombin generation
|
Sun, Siyu
|
|
|
|
21 |
p. 6717-6731
|
artikel
|
| 49 |
Cytokine-induced natural killer cell training is dependent on cellular metabolism and is defective in obesity
|
Kedia-Mehta, Nidhi
|
|
|
|
21 |
p. 4447-4455
|
artikel
|
| 50 |
Decisional involvement and information preferences of patients with hematologic malignancies
|
Loh, Kah Poh
|
|
|
|
21 |
p. 5492-5500
|
artikel
|
| 51 |
Defining the epigenetic status of blood cells using a cyanine-based fluorescent probe for PRMT1
|
Su, Hairui
|
|
|
|
21 |
p. 2829-2836
|
artikel
|
| 52 |
Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial
|
Voskaridou, Ersi
|
|
|
|
21 |
p. 2837-2847
|
artikel
|
| 53 |
DHODH: a promising target in the treatment of T-cell acute lymphoblastic leukemia
|
Sexauer, Amy N.
|
|
|
|
21 |
p. 6685-6701
|
artikel
|
| 54 |
Disease severity and slower psychomotor speed in adults with sickle cell disease
|
Jorgensen, Dana R.
|
|
|
|
21 |
p. 1790-1795
|
artikel
|
| 55 |
Disease site number was not prognostic in a low-risk Hodgkin lymphoma combined modality trial: revisiting PHC HOD90
|
Feraco, Angela M.
|
|
|
|
21 |
p. 6665-6667
|
artikel
|
| 56 |
Disparities in survival of hematologic malignancies in the context of social determinants of health: a systematic review
|
Miranda-Galvis, Marisol
|
|
|
|
21 |
p. 6466-6491
|
artikel
|
| 57 |
Dissecting the role of SWI/SNF component ARID1B in steady-state hematopoiesis
|
Madan, Vikas
|
|
|
|
21 |
p. 6553-6566
|
artikel
|
| 58 |
DNA vs cDNA FLT3-ITD allelic ratio and length measurements in adult acute myeloid leukemia
|
Cucchi, David G.J.
|
|
|
|
21 |
p. 4476-4479
|
artikel
|
| 59 |
Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?
|
Thol, Felicitas
|
|
|
|
21 |
p. 3449-3453
|
artikel
|
| 60 |
Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?
|
Sanz, Guillermo F.
|
|
|
|
21 |
p. 3454-3460
|
artikel
|
| 61 |
Driver mutations in Janus kinases in a mouse model of B-cell leukemia induced by deletion of PU.1 and Spi-B
|
Batista, Carolina R.
|
|
|
|
21 |
p. 2798-2810
|
artikel
|
| 62 |
Editorial Board
|
|
|
|
|
21 |
p. i
|
artikel
|
| 63 |
Editorial Board
|
|
|
|
|
21 |
p. i
|
artikel
|
| 64 |
Editorial Board
|
|
|
|
|
21 |
p. i
|
artikel
|
| 65 |
Editorial Board
|
|
|
|
|
21 |
p. i
|
artikel
|
| 66 |
Editorial Board
|
|
|
|
|
21 |
p. i
|
artikel
|
| 67 |
Editorial Board
|
|
|
|
|
21 |
p. i
|
artikel
|
| 68 |
Editorial Board
|
|
|
|
|
21 |
p. i
|
artikel
|
| 69 |
Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis
|
Reiter, Andreas
|
|
|
|
21 |
p. 5750-5762
|
artikel
|
| 70 |
Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma
|
Facon, Thierry
|
|
|
|
21 |
p. 5449-5459
|
artikel
|
| 71 |
Elevated plasma levels of syndecan-1 and soluble thrombomodulin predict adverse outcomes in thrombotic thrombocytopenic purpura
|
Lu, Ruinan
|
|
|
|
21 |
p. 5378-5388
|
artikel
|
| 72 |
Emerging role of BCR signaling inhibitors in immunomodulation of chronic lymphocytic leukemia
|
Maharaj, Kamira
|
|
|
|
21 |
p. 1867-1875
|
artikel
|
| 73 |
Epigenetic silencing of HTLV-1 expression by the HBZ RNA through interference with the basal transcription machinery
|
Gazon, Hélène
|
|
|
|
21 |
p. 5574-5579
|
artikel
|
| 74 |
Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B
|
Von Drygalski, Annette
|
|
|
|
21 |
p. 3241-3247
|
artikel
|
| 75 |
Evaluating complement dysregulation in livedoid vasculopathy using a functional assay
|
Eswaran, Harish
|
|
|
|
21 |
p. 6604-6607
|
artikel
|
| 76 |
Evaluation of clonal hematopoiesis in pediatric ADA-SCID gene therapy participants
|
White, Shanna L.
|
|
|
|
21 |
p. 5732-5736
|
artikel
|
| 77 |
Even after SARS-CoV-2 booster, there is increased COVID-19 breakthrough infection in patients with plasma cell disorders
|
Fillmore, Nathanael R.
|
|
|
|
21 |
p. 6767-6770
|
artikel
|
| 78 |
First-in-human phase 1 trial of hemoglobin vesicles as artificial red blood cells developed for use as a transfusion alternative
|
Azuma, Hiroshi
|
|
|
|
21 |
p. 5711-5715
|
artikel
|
| 79 |
FOXO activity adaptation safeguards the hematopoietic stem cell compartment in hyperglycemia
|
Govindarajah, Vinothini
|
|
|
|
21 |
p. 5512-5526
|
artikel
|
| 80 |
Frequency of venous thromboembolism in 6513 patients with COVID-19: a retrospective study
|
Hill, Jason B.
|
|
|
|
21 |
p. 5373-5377
|
artikel
|
| 81 |
Front Matter
|
|
|
|
|
21 |
p. ii
|
artikel
|
| 82 |
Front Matter
|
|
|
|
|
21 |
p. ii
|
artikel
|
| 83 |
FUTURES: efficacy and acceptability of a novel reproductive health education program for adolescent males with sickle cell disease
|
Stanek, Charis J.
|
|
|
|
21 |
p. 6648-6651
|
artikel
|
| 84 |
Gender differences in question-asking at the 2019 American Society of Hematology Annual Meeting
|
Moazzam, Saira
|
|
|
|
21 |
p. 5473-5479
|
artikel
|
| 85 |
Gene editing rescue of a novel MPL mutant associated with congenital amegakaryocytic thrombocytopenia
|
Cleyrat, Cédric
|
|
|
|
21 |
p. 1815-1826
|
artikel
|
| 86 |
Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL–negative MPN in blast phase
|
Gupta, Vikas
|
|
|
|
21 |
p. 5562-5573
|
artikel
|
| 87 |
Genetic variants associated with inflammatory bowel disease and gut graft-versus-host disease
|
Martin, Paul J.
|
|
|
|
21 |
p. 4456-4464
|
artikel
|
| 88 |
Genome editing of HBG1 and HBG2 to induce fetal hemoglobin
|
Métais, Jean-Yves
|
|
|
|
21 |
p. 3379-3392
|
artikel
|
| 89 |
Gill S, Vides V, Frey NV, et al. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. Blood Adv. 2022;6(21):5774-5785.
|
|
|
|
|
21 |
p. 6567
|
artikel
|
| 90 |
Handling challenging questions in the management of chronic myeloid leukemia: when is it safe to stop tyrosine kinase inhibitors?
|
Rea, Delphine
|
|
|
|
21 |
p. 5589-5594
|
artikel
|
| 91 |
Hematology referral madness syndrome
|
Djulbegovic, Benjamin
|
|
|
|
21 |
p. 6702-6704
|
artikel
|
| 92 |
Heparin-induced thrombocytopenia in patients with COVID-19: a systematic review and meta-analysis
|
Uaprasert, Noppacharn
|
|
|
|
21 |
p. 4521-4534
|
artikel
|
| 93 |
High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study
|
Zayac, Adam S.
|
|
|
|
21 |
p. 6381-6394
|
artikel
|
| 94 |
High-resolution mapping of the polyclonal immune response to the human platelet alloantigen HPA-1a (PlA1)
|
Zhi, Huiying
|
|
|
|
21 |
p. 3001-3011
|
artikel
|
| 95 |
Human models of NUP98-KDM5A megakaryocytic leukemia in mice contribute to uncovering new biomarkers and therapeutic vulnerabilities
|
Cardin, Sophie
|
|
|
|
21 |
p. 3307-3321
|
artikel
|
| 96 |
Human MYD88 L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells
|
Sewastianik, Tomasz
|
|
|
|
21 |
p. 3360-3374
|
artikel
|
| 97 |
ICANS prophylaxis: potentially transformative but elusive
|
Dowling, Mark R.
|
|
|
|
21 |
p. 6782-6784
|
artikel
|
| 98 |
Impact of somatic and germline mutations on the outcome of systemic mastocytosis
|
Muñoz-González, Javier I.
|
|
|
|
21 |
p. 2814-2828
|
artikel
|
| 99 |
Impact of γδ T cells on clinical outcome of hematopoietic stem cell transplantation: systematic review and meta-analysis
|
Arruda, Lucas C.M.
|
|
|
|
21 |
p. 3436-3448
|
artikel
|
| 100 |
Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy
|
Johnsrud, Andrew
|
|
|
|
21 |
p. 4465-4475
|
artikel
|
| 101 |
Incidence of VTE in asymptomatic children with deficiencies of antithrombin, protein C, and protein S: a prospective cohort study
|
Tormene, Daniela
|
|
|
|
21 |
p. 5442-5448
|
artikel
|
| 102 |
Increased Mac-2 binding protein glycan isomer in patients at risk for late nonrelapse mortality after HSCT
|
Akahoshi, Yu
|
|
|
|
21 |
p. 3287-3296
|
artikel
|
| 103 |
Induction of multiple myeloma bone marrow stromal cell apoptosis by inhibiting extracellular vesicle miR-10a secretion
|
Umezu, Tomohiro
|
|
|
|
21 |
p. 3228-3240
|
artikel
|
| 104 |
Inflammatory reactions mimic residual or recurrent lymphoma on [18F]FDG-PET/CT after CD19-directed CAR T-cell therapy
|
de Boer, Janneke W.
|
|
|
|
21 |
p. 6710-6716
|
artikel
|
| 105 |
In response to “American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults”
|
Reddy, Pavan
|
|
|
|
21 |
p. 5431-5432
|
artikel
|
| 106 |
Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia
|
Hunter, Zachary R.
|
|
|
|
21 |
p. 2937-2946
|
artikel
|
| 107 |
Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma
|
Lin, Yu-Hsiu T.
|
|
|
|
21 |
p. 3214-3227
|
artikel
|
| 108 |
International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies
|
Campbell, Belinda A.
|
|
|
|
21 |
p. 6639-6647
|
artikel
|
| 109 |
Intrathecal alemtuzumab: a potential treatment of refractory leptomeningeal T-cell prolymphocytic leukemia
|
Alsawah, Fares
|
|
|
|
21 |
p. 3333-3336
|
artikel
|
| 110 |
Large-scale in vitro production of red blood cells from human peripheral blood mononuclear cells
|
Heshusius, Steven
|
|
|
|
21 |
p. 3337-3350
|
artikel
|
| 111 |
Late fetal hematopoietic failure results from ZBTB11 deficiency despite abundant HSC specification
|
Cao, Huimin
|
|
|
|
21 |
p. 6506-6519
|
artikel
|
| 112 |
Letermovir prophylaxis in T-cell–depleted transplants: breakthrough and rebound infections in the postmarketing setting
|
Marzolini, Maria A.V.
|
|
|
|
21 |
p. 4500-4503
|
artikel
|
| 113 |
Longitudinal analysis of cardiac abnormalities in pediatric patients with sickle cell anemia and effect of hydroxyurea therapy
|
Dhar, Arushi
|
|
|
|
21 |
p. 4406-4412
|
artikel
|
| 114 |
Long-term outcomes among adults with Langerhans cell histiocytosis
|
Goyal, Gaurav
|
|
|
|
21 |
p. 6568-6578
|
artikel
|
| 115 |
Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy
|
Efficace, Fabio
|
|
|
|
21 |
p. 4370-4379
|
artikel
|
| 116 |
MAF functions as a pioneer transcription factor that initiates and sustains myelomagenesis
|
Katsarou, Alexia
|
|
|
|
21 |
p. 6395-6410
|
artikel
|
| 117 |
Malaria-associated adhesion molecule activation facilitates the destruction of uninfected red blood cells
|
Dalimot, Jill J.
|
|
|
|
21 |
p. 5798-5810
|
artikel
|
| 118 |
Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models
|
Pardanani, Animesh
|
|
|
|
21 |
p. 2964-2972
|
artikel
|
| 119 |
MGUS and clonal hematopoiesis show unrelated clinical and biological trajectories in an older population cohort
|
Da Vià, Matteo Claudio
|
|
|
|
21 |
p. 5702-5706
|
artikel
|
| 120 |
Microbiota modification in hematology: still at the bench or ready for the bedside?
|
Severyn, Christopher J.
|
|
|
|
21 |
p. 3461-3472
|
artikel
|
| 121 |
Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial
|
Sierra, Jorge
|
|
|
|
21 |
p. 6441-6450
|
artikel
|
| 122 |
Molecular subclusters of follicular lymphoma: a report from the United Kingdom’s Haematological Malignancy Research Network
|
Crouch, Simon
|
|
|
|
21 |
p. 5716-5731
|
artikel
|
| 123 |
Monoallelic deletion of BCMA is a frequent feature in multiple myeloma
|
Samur, Mehmet Kemal
|
|
|
|
21 |
p. 6599-6603
|
artikel
|
| 124 |
More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling
|
Bader, Peter
|
|
|
|
21 |
p. 3393-3405
|
artikel
|
| 125 |
Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies
|
Stengel, Anna
|
|
|
|
21 |
p. 4426-4434
|
artikel
|
| 126 |
Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia
|
Chhabra, Saurabh
|
|
|
|
21 |
p. 2922-2936
|
artikel
|
| 127 |
Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow
|
Mazzotti, Céline
|
|
|
|
21 |
p. 2811-2813
|
artikel
|
| 128 |
New therapies for von Willebrand disease
|
Mannucci, Pier Mannuccio
|
|
|
|
21 |
p. 3481-3487
|
artikel
|
| 129 |
Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma
|
Yamshon, Samuel
|
|
|
|
21 |
p. 6579-6588
|
artikel
|
| 130 |
Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry
|
Lemoine, Jean
|
|
|
|
21 |
p. 6589-6598
|
artikel
|
| 131 |
Novel population of human monocyte and osteoclast progenitors from pluripotent stem cells and peripheral blood
|
Root, Sierra H.
|
|
|
|
21 |
p. 4435-4446
|
artikel
|
| 132 |
Outcome of patients with IDH1/2-mutated post–myeloproliferative neoplasm AML in the era of IDH inhibitors
|
Chifotides, Helen T.
|
|
|
|
21 |
p. 5336-5342
|
artikel
|
| 133 |
Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia
|
Huang, Qiu-Sha
|
|
|
|
21 |
p. 3406-3418
|
artikel
|
| 134 |
Patent ductus arteriosus generates neonatal hemolytic jaundice with thrombocytopenia in Upshaw-Schulman syndrome
|
Fujimura, Yoshihiro
|
|
|
|
21 |
p. 3191-3195
|
artikel
|
| 135 |
Pathogen-reduced PRP blocks T-cell activation, induces Treg cells, and promotes TGF-β expression by cDCs and monocytes in mice
|
Tran, Johnson Q.
|
|
|
|
21 |
p. 5547-5561
|
artikel
|
| 136 |
Persistence of endothelial thrombomodulin in a patient with infectious purpura fulminans treated with protein C concentrate
|
Bendapudi, Pavan K.
|
|
|
|
21 |
p. 2917-2921
|
artikel
|
| 137 |
Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia
|
Ravandi, Farhad
|
|
|
|
21 |
p. 6492-6505
|
artikel
|
| 138 |
Platelet CD36 signaling through ERK5 promotes caspase-dependent procoagulant activity and fibrin deposition in vivo
|
Yang, Moua
|
|
|
|
21 |
p. 2848-2861
|
artikel
|
| 139 |
Platelets regulate ischemia-induced revascularization and angiogenesis by secretion of growth factor–modulating factors
|
Nording, Henry
|
|
|
|
21 |
p. 6411-6427
|
artikel
|
| 140 |
Pneumococcal infections in children with sickle cell disease before and after pneumococcal conjugate vaccines
|
Adamkiewicz, Thomas V.
|
|
|
|
21 |
p. 6751-6761
|
artikel
|
| 141 |
Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study
|
Gavriatopoulou, Maria
|
|
|
|
21 |
p. 4398-4405
|
artikel
|
| 142 |
Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GVHD prophylaxis in matched sibling transplantation
|
Kwon, Mi
|
|
|
|
21 |
p. 3351-3359
|
artikel
|
| 143 |
Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL
|
Talleur, Aimee C.
|
|
|
|
21 |
p. 5737-5749
|
artikel
|
| 144 |
Prevalence of inherited blood disorders and associations with malaria and anemia in Malawian children
|
McGann, Patrick T.
|
|
|
|
21 |
p. 3035-3044
|
artikel
|
| 145 |
Processing methods and storage duration impact extracellular vesicle counts in red blood cell units
|
Gamonet, Clementine
|
|
|
|
21 |
p. 5527-5539
|
artikel
|
| 146 |
Prognostic model using 18F-FDG PET radiomics predicts progression-free survival in relapsed/refractory Hodgkin lymphoma
|
Driessen, Julia
|
|
|
|
21 |
p. 6732-6743
|
artikel
|
| 147 |
Public and private human T-cell clones respond differentially to HCMV antigen when boosted by CD3 copotentiation
|
Becher, Laura R.E.
|
|
|
|
21 |
p. 5343-5356
|
artikel
|
| 148 |
Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trials
|
Hantel, Andrew
|
|
|
|
21 |
p. 4352-4360
|
artikel
|
| 149 |
Rational biomarker development for the early and minimally invasive monitoring of AML
|
Abdelhamed, Sherif
|
|
|
|
21 |
p. 4515-4520
|
artikel
|
| 150 |
Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma
|
Schmidts, Andrea
|
|
|
|
21 |
p. 3248-3260
|
artikel
|
| 151 |
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma
|
Pasquini, Marcelo C.
|
|
|
|
21 |
p. 5414-5424
|
artikel
|
| 152 |
Recombinant factor VIII Fc fusion protein drives regulatory macrophage polarization
|
Kis-Toth, Katalin
|
|
|
|
21 |
p. 2904-2916
|
artikel
|
| 153 |
Recurrent CCND3 mutations in MLL-rearranged acute myeloid leukemia
|
Matsuo, Hidemasa
|
|
|
|
21 |
p. 2879-2889
|
artikel
|
| 154 |
Replication timing alterations in leukemia affect clinically relevant chromosome domains
|
Rivera-Mulia, Juan Carlos
|
|
|
|
21 |
p. 3201-3213
|
artikel
|
| 155 |
Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial
|
Ricardi, Umberto
|
|
|
|
21 |
p. 4504-4514
|
artikel
|
| 156 |
R4 RGS proteins suppress engraftment of human hematopoietic stem/progenitor cells by modulating SDF-1/CXCR4 signaling
|
Chan, Kathy Yuen Yee
|
|
|
|
21 |
p. 4380-4392
|
artikel
|
| 157 |
Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa
|
Siegal, Deborah
|
|
|
|
21 |
p. 1827-1838
|
artikel
|
| 158 |
Secondary CNL after SAA reveals insights in leukemic transformation of bone marrow failure syndromes
|
Schmied, Laurent
|
|
|
|
21 |
p. 5540-5546
|
artikel
|
| 159 |
Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients
|
Maffioli, Margherita
|
|
|
|
21 |
p. 3196-3200
|
artikel
|
| 160 |
Should we move to a genomic classification of neutrophilic myeloid neoplasms?
|
Carreño-Tarragona, Gonzalo
|
|
|
|
21 |
p. 6705-6706
|
artikel
|
| 161 |
Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia
|
Maharaj, Kamira
|
|
|
|
21 |
p. 3012-3024
|
artikel
|
| 162 |
Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia
|
Broccoli, Alessandro
|
|
|
|
21 |
p. 6762-6766
|
artikel
|
| 163 |
SNARE-dependent membrane fusion initiates α-granule matrix decondensation in mouse platelets
|
Pokrovskaya, Irina D.
|
|
|
|
21 |
p. 2947-2958
|
artikel
|
| 164 |
Stem cell safe harbor: the hematopoietic stem cell niche in zebrafish
|
Wattrus, Samuel J.
|
|
|
|
21 |
p. 3063-3069
|
artikel
|
| 165 |
Survival outcomes of children with relapsed or refractory myeloid leukemia associated with Down syndrome
|
Raghuram, Nikhil
|
|
|
|
21 |
p. 6532-6539
|
artikel
|
| 166 |
Systematic STAT3 sequencing in patients with unexplained cytopenias identifies unsuspected large granular lymphocytic leukemia
|
Morgan, Elizabeth A.
|
|
|
|
21 |
p. 1786-1789
|
artikel
|
| 167 |
Targeting cyclooxygenase by indomethacin decelerates progression of acute lymphoblastic leukemia in a xenograft model
|
Richartz, Nina
|
|
|
|
21 |
p. 3181-3190
|
artikel
|
| 168 |
T-cell dysfunction by pseudohypoxia and autocrine purinergic signaling in chronic lymphocytic leukemia
|
Montironi, Chiara
|
|
|
|
21 |
p. 6540-6552
|
artikel
|
| 169 |
TG02 inhibits proteasome inhibitor–induced HSF1 serine 326 phosphorylation and heat shock response in multiple myeloma
|
Shah, Shardule P.
|
|
|
|
21 |
p. 1848-1853
|
artikel
|
| 170 |
The bone marrow stroma in human myelodysplastic syndrome reveals alterations that regulate disease progression
|
Kfoury, Youmna S.
|
|
|
|
21 |
p. 6608-6623
|
artikel
|
| 171 |
The design of a Bayesian platform trial to prevent and eradicate inhibitors in patients with hemophilia
|
Bertolet, Marnie
|
|
|
|
21 |
p. 5433-5441
|
artikel
|
| 172 |
The endogenous antimicrobial cathelicidin LL37 induces platelet activation and augments thrombus formation
|
Salamah, Maryam F.
|
|
|
|
21 |
p. 2973-2985
|
artikel
|
| 173 |
The impact of pulmonary function in patients undergoing autologous stem cell transplantation
|
Duque-Afonso, Jesús
|
|
|
|
21 |
p. 4327-4337
|
artikel
|
| 174 |
The microenvironment of DLBCL is characterized by noncanonical macrophages recruited by tumor-derived CCL5
|
Manfroi, Benoît
|
|
|
|
21 |
p. 4338-4351
|
artikel
|
| 175 |
The RBC's road to ghost and removal: splenic clearance
|
Asaro, Robert J.
|
|
|
|
21 |
p. 4422-4425
|
artikel
|
| 176 |
The transition of M-CSF–derived human macrophages to a growth-promoting phenotype
|
Hamidzadeh, Kajal
|
|
|
|
21 |
p. 5460-5472
|
artikel
|
| 177 |
Thrombotic thrombocytopenic purpura and defective apoptosis due to CASP8/10 mutations: the role of mycophenolate mofetil
|
Fioredda, F.
|
|
|
|
21 |
p. 3432-3435
|
artikel
|
| 178 |
Thrombus stability explains the factor V Leiden paradox: a mouse model
|
Shaya, S.A.
|
|
|
|
21 |
p. 3375-3378
|
artikel
|
| 179 |
Timing of treatment of smoldering myeloma: delay until progression
|
Kumar, Shaji K.
|
|
|
|
21 |
p. 3050-3053
|
artikel
|
| 180 |
Timing of treatment of smoldering myeloma: early treatment
|
Mateos, María-Victoria
|
|
|
|
21 |
p. 3045-3049
|
artikel
|
| 181 |
TLR5 signaling in murine bone marrow induces hematopoietic progenitor cell proliferation and aids survival from radiation
|
Zhang, Benyue
|
|
|
|
21 |
p. 1796-1806
|
artikel
|
| 182 |
Treatment and relative survival in very elderly patients with DLBCL in The Netherlands: a population-based study, 1989 to 2015
|
Dinmohamed, Avinash G.
|
|
|
|
21 |
p. 1839-1841
|
artikel
|
| 183 |
Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes
|
Pierson, Sheila K.
|
|
|
|
21 |
p. 6652-6664
|
artikel
|
| 184 |
Treatment strategy for acquired pure red cell aplasia: a systematic review and meta-analysis
|
Lobbes, Hervé
|
|
|
|
21 |
p. 6451-6465
|
artikel
|
| 185 |
Venous thromboembolism in chronic lymphocytic leukemia: a Danish nationwide cohort study
|
Gade, Inger Lise
|
|
|
|
21 |
p. 3025-3034
|
artikel
|
| 186 |
von Willebrand factor modulates immune complexes and the recall response against factor VIII in a murine hemophilia A model
|
Oleshko, Olga
|
|
|
|
21 |
p. 6771-6781
|
artikel
|
| 187 |
When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter
|
Roloff, Gregory W.
|
|
|
|
21 |
p. 3070-3080
|
artikel
|
| 188 |
Which patients are at high risk of recurrent venous thromboembolism (deep vein thrombosis and pulmonary embolism)?
|
Áinle, Fionnuala Ní
|
|
|
|
21 |
p. 5595-5606
|
artikel
|
| 189 |
Whole transcriptome sequencing detects a large number of novel fusion transcripts in patients with AML and MDS
|
Stengel, Anna
|
|
|
|
21 |
p. 5393-5401
|
artikel
|
| 190 |
Who should get long-term anticoagulant therapy for venous thromboembolism and with what?
|
Rodger, Marc Alan
|
|
|
|
21 |
p. 3081-3087
|
artikel
|
Tijdschrift beschrijving